|Last Update: 06/19/13 - 4:00 PM EDT|
|YTD Performance: 65.13%|
|Previous Close: $66.83|
|52 Week Range: $37.52 - $68.62|
|Oustanding Shares: 61,304,811|
|Market Cap: 4,097,000,519|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||1||1||1||1|
|Growth Rate (Year over Year)||3.80%||2.11%||19.67%||27.30%|
SLXP was downgraded from Buy to Hold, ThinkEquity said. $53 price target. Company lacks potential catalysts for the next year.
SLXP was downgraded to Hold, Cantor Fitzgerald said. $59 price target. Company is facing another pipeline setback with Relistor.
If you're a buyer, look at these names as opposed to some of the go-to stocks of the past year.
Shares of SLXP now seen reaching $63, Jefferies said. Estimates also raised on beat and raise. Buy rating.
SLXP was downgraded to Hold, Auriga USA said. $51 price target. Stock is already pricing in potential approval of Relistor and Crofelemer.
Biotech and pharma companies have the biggest edge in pricing power.
SLXP was upgraded to Buy from Hold, Auriga said. $54 price target. 2012 guidance appears conservative.
Shares of SLXP now seen reaching $53, according to Credit Suisse. Estimates also reduced, Company is seeing higher operating costs. Outperform rating.
Contributor Ken Shreve takes a look at upcoming economic data and some key earnings reports for the week of Feb. 27
SLXP was downgraded from Outperform to Market Perform, JMP Securities said. Valuation call, as the stock is already pricing in a lot of good news.